Pharmaceutical company Vivera Pharmaceuticals Inc Wednesday expanded access to testing resources, vaccine clinics and personal protective equipment (PPE) following the new mask and testing mandates across the nation due to increase in COVID-19 cases in the US.
The company has announced a resurgence of hospitalizations due to more transmissible mutations of the Delta variant. The State of California, New York City and the Department of Veteran Affairs have been among the first to announce plans to regularly test unvaccinated employees and advise masks for employees and workers in health care and high-risk congregate settings.
In the State of California, the company offers complimentary, concierge COVID-19 testing solutions for businesses, government establishments, educational institutions, event sites, long-term care facilities as well as other group settings.
According to the company, it continues to support first responders, health care workers and federally qualified health care centres to meet the demand for affordable PPE with an adequate supply of gloves and masks manufactured in the USA as most of the schools reopen. It hopes to help the country get ahead of the curve to slow the spread of COVID-19 to keep communities safe.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
YS Biopharma repays USD40m loan facility
Kintara Therapeutics and TuHURA Biosciences to merge
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine